Nuwellis, Inc. ( NUWE ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Leah McMullen - Director of Communications John Erb - Interim CFO, Interim Principal Financial & Accounting Officer, CEO, President and Chairman Lynn Blake Presentation Operator Good day, everyone, and welcome to today's Nuwellis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's call will be recorded, and I will be standing by should you need any assistance.
Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2025 Earnings Conference Call August 14, 2025 9:00 AM ET Company Participants John L. Erb - CEO, President & Chairman of the Board Leah McMullen - Corporate Participant Robert B.
Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2025 Earnings Conference Call May 13, 2025 9:00 AM ET Company Participants Louisa Smith - IR, Gilmartin Group John Erb - Chairman & Interim CEO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - ROTH Operator Good day, everyone, and welcome to Nuwellis First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
| Health Care Equipment & Supplies Industry | Healthcare Sector | John L. Erb CEO | NASDAQ (CM) Exchange | 67113Y702 CUSIP |
| US Country | 38 Employees | - Last Dividend | 13 Oct 2017 Last Split | 16 Feb 2012 IPO Date |
Nuwellis, Inc. is a pioneering medical device company that specializes in the development, manufacture, and commercialization of unique devices designed for ultrafiltration therapy. Founded in 1999 and initially known as CHF Solutions, Inc., the company rebranded itself as Nuwellis, Inc. in April 2021. With its headquarters in Eden Prairie, Minnesota, Nuwellis has carved a niche in aiding patients who suffer from fluid overload, a condition often associated with heart failure. The company's reach extends beyond the United States, with its products being available through direct sales forces and independent specialty distributors across various countries including Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.
This comprehensive system, a cornerstone of Nuwellis’ products, was designed with the aim of treating patients grappling with fluid overload due to heart failure. The Aquadex FlexFlow system includes a console, a disposable blood circuit set, and a disposable catheter, each component playing a crucial role in the ultrafiltration process. By removing excess fluid from patients, this system helps in alleviating symptoms and improving quality of life.
The Aquadex SmartFlow system represents the evolution in the domain of ultrafiltration therapy by Nuwellis. Although detailed specifics of its features compared to the FlexFlow system aren't outlined here, the naming suggests advancements or improvements aimed at enhancing the efficacy or user-friendliness of the ultrafiltration process. This system, like its predecessor, is targeted at patients suffering from severe fluid overload due to heart failure, underscoring the company's commitment to innovating and improving patient care in this area.